[Pharmacological evaluation of baicalin and jasminoidin and their combination on focal cerebral ischemia-reperfusion injury].
OBJECTIVE
To elucidate the therapeutic effect and the influence on PI3K-Akt-PKB-BAD-CREB-PCREB pathway in focal cerebral ischemia rat responses before and after treatment with baicalin and jasminoidin given alone or in combination.


METHODS
Rat model of ischemia reperfusion was established with thread. Generally accepted methods were used, including TTC staining, behavior test, as well as micro and ultra microscopy which can dynamically and accurately monitor pathological and physiological changes after cerebral ischemia on earlier period, to evaluate the brain injury induced by ischemia and the attenuations by the drugs. The difference of PI3K-Akt-PKB-BAD-CREB-PCREB expression was detected by western-blot technology.


CONCLUSIONS
The combination of baicalin and jasminoidin composition can be potential neuroprotective agent. TTC staining technology combined with behavior grade and ultrmicro-structure observation on brain tissue is effective method to evaluate protective agent, which is related to signal transduction PI3K-Akt-PKB-BAD-CREB-PCREB pathway. The results provide benofical basis for revealing the complex of therapeutic mechanism of traditional Chinese medicine Qingkai Ling (QKL).
Zhang
Zhan-jun
ZJ
Institute of Traditional Chinese Medicine Protection and Utilization in Beijing Normal University, Beijing 100875, China.
Wang
Li-ya
LY
Wang
Zhong
Z
Li
Peng-tao
PT
Wang
Yong-yan
YY
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications / Q000378:metabolism / Q000473:pathology; D050882:CREB-Binding Protein / Q000378:metabolism; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004338:Drug Combinations; D005419:Flavonoids / Q000302:isolation & purification / Q000494:pharmacology*; D032062:Gardenia / Q000737:chemistry; D007267:Injections; D039823:Iridoids / Q000302:isolation & purification / Q000494:pharmacology*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010946:Plants, Medicinal / Q000737:chemistry; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011714:Pyrans / Q000302:isolation & purification / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D031363:Scutellaria / Q000737:chemistry; D015398:Signal Transduction
D017362:Cyclic AMP Response Element-Binding Protein; D004338:Drug Combinations; D005419:Flavonoids; D039823:Iridoids; D018696:Neuroprotective Agents; D011714:Pyrans; C007835:geniposide; C038044:baicalin; D050882:CREB-Binding Protein; D051057:Proto-Oncogene Proteins c-akt